Touchlight

Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus

21 August 2024 -- Hampton, UK -- Touchlight, an innovation-driven contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, is proud to announce the clinical supply of its proprietary dbDNA™ to the University of Nottingham for research and development of a next-generation DNA vaccine targeting the Zika virus.  Scientists from the University of Nottingham...

Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing

Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced a license agreement with GSK, a global leader in biopharmaceutical innovation. This agreement...

Touchlight and LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response

Touchlight to participate in LenioBio’s recently announced grant from CEPI 2 July 2024 -- Hampton, UK, and Düsseldorf, Germany -- LenioBio, a biotech company pioneering cell-free protein production, and Touchlight, the leader in enzymatic DNA production, are pleased to announce a supply agreement aimed at leveraging the revolutionary capabilities of Touchlight’s rapid enzymatic doggybone DNA...

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

9 May 2024 -- Hampton, UK -- Touchlight Genetics, in partnership with the National Physical Laboratory (NPL), have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call.  As the development of genome editing technologies continues to gather pace, Touchlight has developed a novel, circular, single-stranded genome editing template...

University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study

The UK’s Medical Research Council is funding a 10-patient phase 1 study to deliver rapid personalised treatment for lung cancer patients 3 April 2024 -- Hampton, UK -- Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA) technology, today announced an agreement with University of Liverpool, UK, for the...

Touchlight Awarded Tender to Supply Enzymatic dbDNA to CPI’s RNA Centre of Excellence

28 March 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA) technology and leaders in enzymatic DNA production, is delighted to announce that it has been awarded a tender to deliver enzymatic DNA as part of CPI’s tender process for the establishment of its...
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

+44 20 8481 9200